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Abstract
Trisomy X is a sex chromosome anomaly with a variable phenotype caused by the presence of an extra X chromosome 
in females (47,XXX instead of 46,XX). It is the most common female chromosomal abnormality, occurring in 
approximately 1 in 1,000 female births. As some individuals are only mildly affected or asymptomatic, it is estimated 
that only 10% of individuals with trisomy X are actually diagnosed. The most common physical features include tall 
stature, epicanthal folds, hypotonia and clinodactyly. Seizures, renal and genitourinary abnormalities, and premature 
ovarian failure (POF) can also be associated findings. Children with trisomy X have higher rates of motor and speech 
delays, with an increased risk of cognitive deficits and learning disabilities in the school-age years. Psychological 
features including attention deficits, mood disorders (anxiety and depression), and other psychological disorders are 
also more common than in the general population. Trisomy X most commonly occurs as a result of nondisjunction 
during meiosis, although postzygotic nondisjunction occurs in approximately 20% of cases. The risk of trisomy X 
increases with advanced maternal age. The phenotype in trisomy X is hypothesized to result from overexpression of 
genes that escape X-inactivation, but genotype-phenotype relationships remain to be defined. Diagnosis during the 
prenatal period by amniocentesis or chorionic villi sampling is common. Indications for postnatal diagnoses most 
commonly include developmental delays or hypotonia, learning disabilities, emotional or behavioral difficulties, or POF. 
Differential diagnosis prior to definitive karyotype results includes fragile X, tetrasomy X, pentasomy X, and Turner 
syndrome mosaicism. Genetic counseling is recommended. Patients diagnosed in the prenatal period should be 
followed closely for developmental delays so that early intervention therapies can be implemented as needed. School-
age children and adolescents benefit from a psychological evaluation with an emphasis on identifying and developing 
an intervention plan for problems in cognitive/academic skills, language, and/or social-emotional development. 
Adolescents and adult women presenting with late menarche, menstrual irregularities, or fertility problems should be 
evaluated for POF. Patients should be referred to support organizations to receive individual and family support. The 
prognosis is variable, depending on the severity of the manifestations and on the quality and timing of treatment.
Background/Definition
Trisomy X (47,XXX) is a sex chromosome aneuploidy
condition in which females have an extra X chromosome,
compared to the 46,XX karyotype in typical females. It
was first described in 1959 in a 35-year-old woman with
normal intellectual abilities who presented with second-
ary amenorrhea at 19 years of age [1]. Since the initial
description, only several hundred cases have been
described, identifying a variety of associated develop-
mental, psychological, and medical features. Most of the
background literature on trisomy X comes from longitu-
dinal prospective studies of females identified by new-
born screening and followed into young adulthood.
These studies were conducted in the 1970's and 80's at
multiple centers across the U.S., Canada, and the U.K. [2-
5]. While newborn screening studies have demonstrated
that the incidence of trisomy X is approximately 1/1000
female births, only approximately 10% of cases are ascer-
tained clinically. There is considerable variation in the
phenotype, with some individuals very mildly affected
and others with more significant physical and psychologi-
cal features. This manuscript reviews the current litera-
ture available describing features associated with trisomy
X, with recognition that much of the literature is based
on small sample sizes and clinical ascertainment of
patients, and does not likely represent the full spectrum
of females with trisomy X. However, review of the current
knowledge is necessary to provide a summary of back-
ground and treatment recommendations for patients and
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professionals, and to highlight the many areas of need for
additional research in trisomy X.
Disease Names/Synonyms
Trisomy X is also commonly known as:
47,XXX
Triple X, or
Triplo-X
Epidemiology
Originally described as the "superfemale" in 1959, tri-
somy X occurs in approximately 1 in 1,000 female births,
however, it is estimated that only approximately 10% of
cases are diagnosed [6]. In identified cases, diagnosis
occurs through prenatal amniocentesis or chorionic villi
sampling (CVS), or in the postnatal period through a
standard karyotype test or chromosome analysis per-
formed for hypotonia, developmental delays, physical
features, or cognitive/behavioral difficulties. Although
nonmosaic 47,XXX karyotypes are the most frequent,
mosaicism occurs in approximately 10% of cases and can
occur in many combinations such as 46,XX/47,XXX or
47,XXX/48,XXXX, or in combinations including Turner
syndrome cell lines such as 45,X/47,XXX or 45,X/46,XX/
47,XXX[6].
Clinical Description
A. Physical Characteristics
Significant facial dysmorphology or striking physical fea-
tures are not commonly associated with 47,XXX, how-
ever, minor physical findings can be present in some
individuals including epicanthal folds, hypertelorism,
upslanting palpebral fissures, clinodactyly, overlapping
digits, pes planus, and pectus excavatum. Hypotonia and
joint hyperextensibility may also be present [2,7]. Please
see Figure 1 for photographs of girls with trisomy X, and
Table 1 for a summary of physical and medical features.
Length and weight at birth is usually normal for gesta-
tional age, however, stature typically increases in early
childhood, and by adolescence most girls with 47,XXX
are at or above the 75th percentile for height [2]. A few
cases have been ascertained due to tall stature [8], and
current evaluation of tall stature in females should
include karyotype analysis to evaluate for 47,XXX. Cases
of short stature have also been described (unrelated to a
known 45,X mosaicism), and one prospective study iden-
tified a subgroup of 47,XXX girls with heights below the
50th percentile [9]. Body segment proportions typically
show long legs, with a short sitting height [10]. Studies of
bone age have shown no significant differences from
46,XX females [11]. The average head circumference is
below the 50th percentile, however, there is a lot of indi-
vidual variation. Microcephaly (<5th percentile) is rare
[12,13].
B. Clinical characteristics
Although major medical problems are not present in
most cases, other medical problems may be associated
with trisomy X. The most common are genitourinary
abnormalities, ranging from unilateral kidney and renal
dysplasia to ovarian malformations [14]. Congenital heart
defects have also been described including cases of atrial
and ventricular septal defects, pulmonic stenosis, and
aortic coarctation [15-17]. Studies describing seizure dis-
orders and EEG abnormalities in trisomy X vary from 0 to
Table 1: Physical and Medical Features Associated with 
Trisomy X
Feature Estimated frequency based 
on current available data 
[10,19,22,33,44]
Tall stature >75th percentile 80-89%
Epicanthal folds 32-46%
Clinodactyly 42-65%
Hypotonia in infancy 55-71%
Genitourinary malformations 5-16%
Seizure disorder 11-15%
Intention tremor 6-20%
Congenital hip dysplasia 2-12%
Constipation/Abdominal 
pains
12-45%
Premature ovarian failure unknown
Figure 1 Variable facial features in girls with trisomy X. (a) Epican-
thal folds and hypertelorism in 2 year old girl, (b) Hypertelorism in 9 
year old girl, (c) Lack of dysmorphic features in a 19 year old girl with 
trisomy X.
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65% depending on the cohort studied and means of ascer-
tainment, however, in the largest cohorts clinical seizures
are present in approximately 15% of cases. Seizure sub-
types including absence, partial, and generalized seizures
have been described, with good responses to standard
anticonvulsant treatments [18-21]. Gastrointestinal prob-
lems, including constipation and abdominal pain, are also
common concerns [2,22].
Pubertal onset and sexual development are usually nor-
mal in trisomy X, however, there have been cases of ovar-
ian or uterine dysgenesis described in children and young
adults with trisomy X. Premature ovarian failure (POF) is
a condition in which the ovarian functions of hormone
production and oocyte (egg) development become
impaired before the typical age for menopause. There are
multiple case reports of women with trisomy X found to
have POF, with endocrine findings of hypergonadotropic
hypogonadism. The ages of these cases have ranged from
19 to 40 years [1,23,24]. Studies on the prevalence of POF
in adolescents or adults with trisomy X have not yet been
performed. One study that performed genetic screening
on women presenting with POF identified trisomy X in
3% of cases [25]. In trisomy X, a large percentage of the
reported cases of POF have also been associated with
other autoimmune diseases [23,26,27], including autoim-
mune thyroid disorder [25].
Precocious puberty has also been described but is not a
typical finding. There have been no direct studies of fer-
tility in trisomy X, however, many reports of successful
pregnancies have been described, and fertility is likely
normal in most cases unless complicated by a genitouri-
nary malformation or POF as described above [2]. There
is a significant need for more research in this area in the
trisomy X population.
c. Developmental and Psychological Characteristics
There is significant variability in the developmental and
psychological features of children and adults with trisomy
X, ranging from those with minimal involvement to those
with clinically significant problems requiring comprehen-
sive intervention services. Thus, individual evaluation of
developmental and psychological problems known to be
associated with trisomy X is important in each individual.
Infants and toddlers are at increased risk for early
developmental delays, especially in speech-language
development and motor development related to hypoto-
nia. Average age at walking independently is 16.2 months
(range 11-22 months), and for first words is 18.5 months
(range 12 - 40 months) [2]. Prospective studies compar-
ing girls with trisomy X at 24 months of age to sibling
controls show impairments in speech and language
development. Expressive language may be more impaired
than receptive language, with a pattern described as
developmental dyspraxia in some patients. However,
other patients show impairments in both expressive and
receptive language [28]. Speech and language deficits
may continue throughout childhood into adulthood, with
higher level language difficulties including problems with
language processing, verbal fluency, language compre-
hension, and pragmatic language in some patients
[2,28,29].
Studies on cognitive abilities in trisomy X also show a
wide range of cognitive skills, with full scale IQ's ranging
from 55-115 across various studies [28-34]. While there
are clearly many girls with trisomy X with cognitive skills
in the average to above average range, cognitive deficits
and learning disabilities are more common than in the
general population and when compared to sibling con-
trols. IQ subscales most commonly reveal deficits in ver-
bal IQ compared to nonverbal/performance IQ, however,
many patients with trisomy X have cognitive deficits
across both verbal and nonverbal domains
[3,29,32,35,36]. While cognitive deficits in the intellectual
disability (mental retardation) range are rare, intellectual
disability is more common than in the general population
with the mean full scale IQ at 85-90 and approximately 5-
10% with intellectual disability [37]. See Figure 2.
Motor skill deficits may also be present. Walking may
be delayed, and decreased muscle tone and lack of coor-
dination are often clinically significant. An extensive
motor study of 10 children with trisomy X showed ongo-
ing motor planning difficulties and overall weaknesses in
motor skills and motor coordination, along with gait
abnormalities and poor joint stability [2,38].
Attentional problems, poor executive function, and
decreased adaptive functioning skills may also impact
educational and home functioning. Attention deficit
hyperactivity disorder (ADHD) is present in 25-35% of
cases, with symptoms of inattention, distractibility, and
Figure 2 Estimated Full-Scale IQ (FSIQ) distribution for females 
with 47,XXX compared to controls. In 47,XXX, there is a wide varia-
tion in IQ with the normal curve shifted to the left with the mean FSIQ 
at 85-90. The majority of females with 47,XXX have a FSIQ in the normal 
range, and many are above average compared to the general popula-
tion. However, due to the shift of the curve, a larger percentage of fe-
males with 47,XXX fall in the intellectual disability range compared to 
controls. Adapted and reprinted with permission from Bender et. al. 
1986 [42].
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poor organization typically more significant than hyper-
activity [29,39].
There is a paucity of research on mental health prob-
lems in trisomy X, however, increased rates of anxiety,
depression/dysthymia and adjustment disorders have
been described in previous studies [2,40]. Anxiety con-
cerns are mostly related to social avoidance, generalized
anxiety and separation anxiety, and can present in the
early school age years or in adolescence. Childhood anxi-
ety and language weaknesses are a difficult combination
for affected children as the demanding verbal environ-
ments often found in school settings can exacerbate anxi-
ety and result in behavioral difficulties. Language deficits
may also impact social adjustment in some children when
they have difficulty communicating with playmates and
when self-expression is limited in older children and ado-
lescents. Social immaturity relative to peers may be pres-
ent, and this, along with cognitive and executive function
impairments, can make some girls with trisomy X vulner-
able to social pressures from peers and victimization.
Other mental health disorders (including adjustment dis-
orders, mood disorders and psychotic disorders) have
been described in case series and reports [2,41-43], and
comprehensive studies evaluating features of these disor-
ders in the trisomy X population are needed. A compre-
hensive review of trisomy X literature with an emphasis
on mental health has recently been published by Otter et
al. [44]. Again, the variability in the phenotype needs to
be emphasized, since many females with trisomy X have
minimal cognitive, social, or emotional difficulties.
d. Neuroimaging studies
Since the longitudinal studies of the 1970's and 80's of
females with trisomy X followed into adulthood, there
have been very few additional research studies focused
exclusively on this genetic disorder. A neuroimaging
study conducted in 2002 in 10 girls with trisomy X from
the original longitudinal cohort in Denver (mean age 29.1
years) showed that whole brain volumes were signifi-
cantly reduced compared to controls, and a slight reduc-
tion in the size of the amygdala was also noted [45].
Another MRI study of 12 girls with trisomy X (mean age
21.6) from a birth cohort in the UK confirmed smaller
whole brain volumes, and there was a significant correla-
tion between smaller brain volumes and lower cognitive
scores on two measures (the national adult reading test/
NART and the Quick test) [46]. This study also reported
findings of white matter "high intensity foci" (HIS) in 27%
of females with trisomy X, similar to those seen in other
sex chromosome aneuploidy groups in their study (XXY
and XYY), and in other sex chromosome aneuploidy pop-
ulations such as 48,XXYY and 49,XXXXY [47,48]. The
significance or neuropathological findings of these white
matter abnormalities are not yet known, however, they
suggest that gene dosage effects from sex chromosome
genes affect white matter development.
Genetics
In typical 46,XX females, only one X chromosome in
each cell is genetically active and the other is inactivated
through DNA methylation and the accumulation of a his-
tone variant throughout the chromosome [49]. X-inacti-
vation occurs early in blastogenesis and is controlled by
the X chromosome inactivation center (XIC), which
counts the X chromosomes present and randomly inacti-
vates all but one X chromosome per diploid set. The ran-
domly selected X chromosome silences itself by
expressing the XIST and Tsix genes. However, particular
segments of the X chromosome, known as the pseudoau-
tosomal regions (PAR1 and PAR2), have Y chromosome
homologs and therefore are not inactivated and remain
genetically active [50,51]. Approximately 5-10% of addi-
tional genes on the X chromosome outside the PAR
regions also escape X-inactivation. Thus, in trisomy X,
two of the three X chromosomes are inactivated, how-
ever, genes in the PAR regions and other genes that
escape X-inactivation are expressed from the three X
chromosomes. It is hypothesized that the phenotypic
abnormalities associated with trisomy X result from over-
expression of these genes on the X chromosome that
escape X-inactivation [30,52,53]. While there is some
microarray evidence of overexpression of X-chromosome
genes in cells lines with supernumerary X chromosomes
[54], the specific genes involved in the phenotype of tri-
somy X and other sex chromosome aneuploidies have not
been identified. One exception is the SHOX gene, which
escapes X-inactivation and is associated with the short
stature seen in Turner syndrome and the tall stature in
supernumerary sex chromosome aneuploidy conditions
[55,56].
Etiology
Trisomy X occurs from a nondisjunction event, in which
the X chromosomes fail to properly separate during cell
division either during gametogenesis (resulting in a tri-
somic conceptus), or after conception (known as post-
zygotic nondisjunction). Studies of the parental origin of
the additional X chromosome in trisomy X demonstrated
that 58-63% of cases were derived from maternal meiosis
I errors, 16-17.4% were derived from maternal meiosis II
errors and 18-19.6% were derived from post-zygotic non-
disjunction [57,58].
Similar to other trisomies, trisomy X has been shown to
have a statistically significant correlation with advancing
maternal age, as the likelihood of nondisjunction events
during meiosis increases with increasing maternal age. In
one study, mosaic trisomy X (such as 45,X/47,XXX) did
not demonstrate a significant age-dependent correlation,Tartaglia et al. Orphanet Journal of Rare Diseases 2010, 5:8
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suggesting that cases of mosaicism may result from a
post-zygotic nondisjunction event [59]. However, cases of
46,XX/47,XXX and 45,X/47,XXX mosaicism may also
result from a post-zygotic trisomy rescue.
Diagnosis
Karyotype analysis of peripheral blood is the most stan-
dard test used to make the diagnosis. Prenatal amniocen-
tesis or CVS also identify a percentage of patients with
trisomy X, however, confirmation studies are recom-
mended after birth via FISH to study 50+ cells in order to
evaluate for mosaicism. It is also important to identify
mosaicism with a Turner syndrome (45,X) cell line in
order to determine appropriate medical evaluations and
treatments needed for Turner syndrome.
The physical and psychological manifestations of tri-
somy X are variable, and a karyotype should be consid-
ered in females presenting with:
▪ Developmental delays (speech and/or motor)
▪ Hypotonia
▪ Hypertelorism/Epicanthal folds/Clinodactyly
▪ Tall stature
▪ Premature Ovarian Failure/Primary Ovarian Insuffi-
ciency
▪ Learning Disability/Intellectual Disability
▪ Attention deficits/Attention Deficit/Hyperactivity
Disorder (ADHD)
▪ Anxiety, Mood disorders, or other psychiatric symp-
toms
Differential Diagnosis
Developmental and behavioral features in trisomy X can
be similar to those seen in females with fragile X syn-
drome. Females suspected of having fragile X with a neg-
ative fragile X test should have a karyotype completed to
evaluate for trisomy X [16].
Tetrasomy X and pentasomy X syndromes share most
features of trisomy X, however , they are usually associ-
ated with more significant developmental delays, dys-
morphic features (absent in trisomy X), and congenital
malformations compared to trisomy X [16,53]. Females
with pentasomy X typically have short stature [56].
Due to features in the newborn period such as hypoto-
nia, hypertelorism and epicanthal folds, some patients
with trisomy X are ascertained by karyotype performed
due to suspicion for trisomy 21 or trisomy 21 mosaicism.
Other genetic conditions associated with tall stature
could also be considered depending on the clinical pre-
sentation, such as Marfan syndrome (long limbs, hyper-
extensibility), and the Sotos' and Beckwith-Weidemann
syndromes (cognitive impairments).
Adolescents or adult females presenting with POF
should be tested for trisomy X, Turner syndrome, and the
fragile X premutation, and should have further evaluation
to identify other possible medical causes of POF.
Females with trisomy X may first present with a clinical
picture that leads to a diagnosis of a neurodevelopmental
disorder such as speech-language disorder, learning dis-
ability, ADHD, autism spectrum disorder, or anxiety/
mood disorder. Individuals with these diagnoses should
be further evaluated medically to determine if testing for
trisomy X or other medical conditions is indicated.
The differential diagnosis is eliminated after results of a
karyotype analysis show trisomy X (47,XXX), unless
there are significant impairments (moderate or severe
intellectual disability), congenital malformations, or med-
ical problems not consistent with the trisomy X pheno-
type. In these cases, additional genetic and medical
evaluation is warranted to rule out other disorders, since
these may co-exist with trisomy X due to the high inci-
dence of 1:1000 births.
Also, a 47,XXX cell line is present in 5-15% of females
with Turner syndrome. Karyotype testing of females pre-
senting with short stature and a Turner syndrome pheno-
type have shown findings of nonmosaic 47,XXX in blood
lymphocytes, however, genetic testing of another tissue
such as skin biopsy or buccal cells identified 45,X mosa-
icism [59]. Thus, individuals found to have trisomy X
with a Turner syndrome phenotype should have a second
tissue type analyzed by cytogenetic or FISH studies to
further evaluate for a 45,X cell line since this changes
treatment recommendations.
Genetic Counseling For Trisomy X
Genetic counseling for prenatally diagnosed cases of tri-
somy X should address the medical, developmental, and
psychological manifestations of the condition as outlined
in this review. As noted, there is significant variability in
developmental delays, learning disabilities and psycho-
logical characteristics in trisomy X and it is not yet possi-
ble to predetermine which child will exhibit any or all of
these concerns. Couples with a recent diagnosis may be
eager to search the internet for information about tri-
somy X and they should be cautioned about the excessive
inaccurate and biased information they may find. Cou-
ples should be informed of the high frequency of trisomy
X (1 per 1000 female births) and that most girls go undi-
agnosed, in order to support them in understanding and
accepting that their diagnosis is not an isolated case with
a predetermined outcome [46]. Some couples have found
it helpful to talk with other parents of trisomy X children
(resource: KS&A (Knowledge, Support & Action),
UNIQUE, Triplo-X support group) [60-62]. Couples
should be informed that the occurrence of trisomy X is
due to a random event, that there is nothing that they did
to cause or prevent the occurrence. It is important forTartaglia et al. Orphanet Journal of Rare Diseases 2010, 5:8
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parents to appreciate the significant role of other genes
inherited, stressing that the child's prognosis is relative to
their entire genetic makeup, as well as the impact of envi-
ronmental factors. In addition, a study of females with tri-
s o m y  X  b y  R o b i n s o n  e t  a l .  d e m o n s t r a t e d  t h a t  f e m a l e s
diagnosed in the prenatal period had better developmen-
tal and educational outcomes and more typical peer rela-
tionships in comparison to girls diagnosed in the
postnatal period [63]. However, this study may be biased
as it was based on a small sample of patients and did not
control for several environmental influences, such as
socioeconomic status and family support.
Couples should be informed that fetal survival rate is
g o o d ,  w i t h  9 9 %  s u r v i v i n g  t o  t e r m  f o l l o w i n g  d i a g n o s i s
after amniocentesis [64,65]. It is not routine to karyotype
parents of girls with 47,XXX as recurrence risk is esti-
mated to be <1% [66-68]. Similar to other aneuploidies, a
significant maternal age effect has been demonstrated
with an increasing risk specific to trisomy X of 1/2500
live births at a maternal age of 33 to 1/450 live births at a
maternal age of 43 [69]. Studies reporting elective termi-
nation rates following a prenatal diagnosis vary by loca-
tion of the study, with the most recent reports from the
U.S. and France ranging from 25-40% [70,71]. These rates
are lower compared to other sex chromosome aneuploidy
conditions due to the lack of association with infertility
and other serious medical problems, and the broad phe-
notypic variability. For couples who choose to continue
an affected pregnancy, it is recommended that the
genetic counselor assist the family in identifying commu-
nity resources for developmental assessments and early
intervention services due to the increased risk for devel-
o p m e n t a l  d e l a y s  a s  o u t l i n e d  i n  t h i s  r e v i e w .  F o l l o w - u p
postnatal karyotyping is also recommended due to mosa-
icism in approximately 10% of cases and the potential
impact for the medical and developmental management
of the child [6].
When discussing the diagnosis with the child, it is
important to use terminology that is straightforward and
developmentally appropriate. Young children should be
given simple, age-appropriate information on a fairly reg-
ular basis allowing them to grow, cope and adjust to the
information over time. With a young child, it is important
to dispel fears of the disorder being lethal or contagious,
and to explain that it is not her parents' fault. Discussions
with adolescents and young adult children should be
straightforward with full disclosure. Use of the term "sex"
o r  " s e x  c h r o m o s o m e "  s h o u l d  b e  u s e d  w i t h  c a u t i o n ,  a s
children and adolescents can confuse the diagnosis with
their sexuality or misconstrue the diagnosis as having a
"sex abnormality." Open communication should be
encouraged and questions addressed directly. If the par-
ent does not feel well-informed or prepared to answer
questions, seeking input from professionals, such as a
physician or genetic counselor, is recommended.
Genetic counseling for adult patients should addition-
ally address potential reproductive issues, specifically
POF and the risk of transmission. While fertility in
women with trisomy X is generally considered normal,
there is an increased risk for POF as noted within this
review, which may be important to consider in family
planning. Furthermore, patients should be counseled that
the transmission of X aneuploidy (extra or missing X
chromosomes) from women with trisomy X is rare,
although it has been reported [68]. Although some
reports support a <5% increased risk for chromosomally
abnormal offspring [3,72], more recent figures support
that <1% may be more accurate. It is important that this
risk be presented independently of the risks due to mater-
nal age. These transmission risks apply only to women
with non-mosaic 47,XXX, as mosaicism may increase the
risk of X aneuploidy and potential outcomes, so each sce-
nario should be considered individually [3,72,73].
Management
Evaluation and treatment recommendations depend on
the age of the patient and severity of the phenotype, how-
ever, all individuals should undergo a medical history and
physical examination with an emphasis on features
requiring monitoring and intervention as outlined in this
review. Infants and children with trisomy X should
undergo evaluation for the psychological and medical
features of the disorder. In infants and young children, a
renal ultrasound and cardiac evaluation should be
obtained. Constipation should be treated as needed.
Medical history should include questions regarding star-
ing spells or atypical movements, since seizure disorders
and electroencephalogram (EEG) abnormalities can be
present in females with trisomy X and may present as
partial or absence seizures. In these cases, EEG studies
should be performed to rule out possible seizure activity.
Adolescents and adult women presenting with late
menarche, menstrual irregularities, or problems with fer-
tility should be evaluated by an endocrinologist or gyne-
cologist for hormonal abnormalities that may signal
ovarian insufficiency which can be associated with tri-
somy X. Other autoimmune problems including thyroid
problems should also be considered.
A comprehensive developmental evaluation is impor-
tant for newly diagnosed infants and young children, and
between 6-12 months of age for infants diagnosed in the
prenatal period. The assessment should include special
emphasis on language, motor, and social development.
Early developmental stimulation, speech therapy, occupa-
tional therapy and/or physical therapy should be consid-
ered, especially if assessment results show scores withinTartaglia et al. Orphanet Journal of Rare Diseases 2010, 5:8
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the delayed or borderline range. For school-age children
and adolescents, a multidisciplinary assessment, includ-
ing evaluation with a child psychologist (for learning dis-
abilities, social/emotional problems, and adaptive
functioning assessment), as well as speech/language
assessment and occupational therapy assessment, is
important in order to identify strengths and weaknesses
and to help develop educational supports and behavioral
interventions. Common problems including learning dis-
abilities, speech-language disorders (including apraxia of
speech), ADHD with predominantly inattentive symp-
toms, executive dysfunction, anxiety disorders, social dif-
ficulties, and other mental health problems should be
considered and treated if problematic. Consultation with
a developmental pediatrician, psychiatrist, or neurologist
is important in females with trisomy X who have associ-
ated ADHD, anxiety, and other mental health problems
to discuss possible behavioral and/or medication treat-
ments. In females with trisomy X who have these condi-
tions, medication treatments are the same as for the
general population, however, low starting doses are rec-
ommended due to the more complex neurodevelopmen-
tal involvement in trisomy X.
It is important for evaluators to recognize that behav-
ioral symptoms related to learning disabilities, ADHD,
language comprehension deficits, and anxiety may have
significant overlap, and thus consideration and treatment
of all the comorbidities are important in developing a
treatment plan. Psychological therapy and counselling
can be effective as a part of the treatment plan if needed,
however , may need to be modified based on the recep-
tive-expressive language and cognitive abilities of the
patient. If present, developmental concerns and educa-
tional struggles should be addressed aggressively instead
of taking a "wait and see" approach, since they are
unlikely to improve or "catch up" without targeted inter-
ventions, and delaying treatment will lead to poorer out-
comes. Assessment and documentation of adaptive
functioning (life skills) in domains including self-care,
communication, social, community use, safety, and self-
direction is important to identify strengths and weak-
nesses in these areas. A subset of females with trisomy X
has borderline cognitive abilities or learning disabilities
with adaptive functioning in the disability range, and in
this group adaptive functioning assessment is important
to support the need for community services and disability
supports through adulthood.
Family Support
Family support can be a very important part of treatment,
especially for families of girls with more severe medical
or psychological features of trisomy X. Support organiza-
tions include KS&A in the U.S., UNIQUE in Europe, and
a Triplo-X internet-based support group supporting fam-
ilies internationally [60-62]. Families of children and
young adults with trisomy X and associated developmen-
tal delays or mental health problems should also be
encouraged to seek out local support groups for general
developmental disabilities or mental health problems
since these organizations have access to resources in the
local area for the family.
Prognosis
The prognosis of trisomy X is variable, with some indi-
viduals doing extremely well with minimal manifestations
of the disorder, and others with more significant cogni-
tive and psychological involvement as described above.
Outcomes of those diagnosed in the prenatal period have
been found to be better than those of patients described
in the prospective studies (birth cohorts) and than those
in case reports of girls identified after birth ascertained
due to developmental delays [64]. Girls with 46,XX/
47,XXX mosaicism also have improved outcomes com-
pared to those with 100% 47,XXX [37].
Unresolved Questions
There are many unresolved questions in trisomy X, as
this genetic disorder has received very little attention by
scientists or clinicians since the completion of the pro-
spective, descriptive studies of the 1970's and 80's. Addi-
tional research on the pathophysiology and genetic
mechanisms involved in the associated medical problems
(such as seizures and POF) is needed. Elucidation of the
specific genes, gene pathways, and genetic mechanisms
involved in the phenotype and phenotypic variability will
help to understand the pathophysiology, improve genetic
counseling, and perhaps lead to targeted treatments in
the future. Clinical studies are also needed to further
characterize the psychological features and neurodevel-
opmental disorders, and to study specific interventions
for developmental delays, learning disabilities, and psy-
chiatric problems in this population, in order to guide
parents, educators, and mental health professionals.
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